Inflammatory breast cancer response to modern neoadjuvant chemotherapy: Tumor response and survival outcomes

IF 2.7 3区医学 Q1 SURGERY American journal of surgery Pub Date : 2025-05-01 Epub Date: 2025-03-05 DOI:10.1016/j.amjsurg.2025.116288

Dorsa Mousa-Doust , Amy Bazzarelli , Melina Deban , Carol Dingee , Jieun Newman-Bremang , Jin-Si Pao , Rebecca Warburton , Elaine McKevitt

{"title":"Inflammatory breast cancer response to modern neoadjuvant chemotherapy: Tumor response and survival outcomes","authors":"Dorsa Mousa-Doust , Amy Bazzarelli , Melina Deban , Carol Dingee , Jieun Newman-Bremang , Jin-Si Pao , Rebecca Warburton , Elaine McKevitt","doi":"10.1016/j.amjsurg.2025.116288","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer. This study evaluates oncologic outcomes in IBC patients treated with modern multimodal treatment.</div></div><div><h3>Methods</h3><div>A retrospective review analyzed clinicopathologic data of 5063 patients, 646 of whom underwent NAC followed by surgery between 2012 and 2024. Survival outcomes were compared across biologic subtypes.</div></div><div><h3>Results</h3><div>Twenty-six cases of T4dM0 IBC were identified, with 57.7 % HER-2 positive, 26.9 % ER positive/HER-2 negative, and 15.4 % ER negative/HER-2 negative. The total pCR rate was highest in HER-2 positive (53.3 %) and lowest in ER-positive/HER-2 negative patients (p = 0.036). Among 19 patients with ≥3 years of follow-up, 47 % experienced recurrence (78 % distant and 22 % locoregional) and 42 % died of breast cancer. No significant differences in locoregional recurrence, or survival outcomes were found across subtypes.</div></div><div><h3>Conclusion</h3><div>pCR has limited prognostic value in IBC. Although HER-2 positive patients are more likely to achieve pCR, this does not necessarily translate into improved outcomes.</div></div>","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":"243 ","pages":"Article 116288"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002961025001102","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer. This study evaluates oncologic outcomes in IBC patients treated with modern multimodal treatment.

Methods

A retrospective review analyzed clinicopathologic data of 5063 patients, 646 of whom underwent NAC followed by surgery between 2012 and 2024. Survival outcomes were compared across biologic subtypes.

Results

Twenty-six cases of T4dM0 IBC were identified, with 57.7 % HER-2 positive, 26.9 % ER positive/HER-2 negative, and 15.4 % ER negative/HER-2 negative. The total pCR rate was highest in HER-2 positive (53.3 %) and lowest in ER-positive/HER-2 negative patients (p = 0.036). Among 19 patients with ≥3 years of follow-up, 47 % experienced recurrence (78 % distant and 22 % locoregional) and 42 % died of breast cancer. No significant differences in locoregional recurrence, or survival outcomes were found across subtypes.

Conclusion

pCR has limited prognostic value in IBC. Although HER-2 positive patients are more likely to achieve pCR, this does not necessarily translate into improved outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

炎性乳腺癌对现代新辅助化疗的反应：肿瘤反应和生存结果

背景炎性乳腺癌（IBC）是一种罕见的侵袭性乳腺癌。本研究评估了接受现代多模式治疗的 IBC 患者的肿瘤学结果。方法回顾性分析了 5063 例患者的临床病理学数据，其中 646 例患者在 2012 年至 2024 年期间接受了 NAC 治疗，随后进行了手术。结果共发现 26 例 T4dM0 IBC，其中 HER-2 阳性占 57.7%，ER 阳性/HER-2 阴性占 26.9%，ER 阴性/HER-2 阴性占 15.4%。HER-2阳性患者的总pCR率最高（53.3%），ER阳性/HER-2阴性患者的总pCR率最低（p = 0.036）。在随访时间≥3年的19名患者中，47%的患者复发（78%为远处复发，22%为局部复发），42%死于乳腺癌。不同亚型的局部复发率或生存率没有明显差异。尽管HER-2阳性患者更有可能获得pCR，但这并不一定会改善预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.